LPS-induced bronchoalveolar neutrophilia; effects of salmeterol treatmentWALLIN, Annika; POURAZAR, Jamshid; SANDSTRÖM, Thomas et al.Respiratory medicine. 2004, Vol 98, Num 11, pp 1087-1092, issn 0954-6111, 6 p.Article

The functional impact of adding salmeterol and tiotropium in patients with stable COPDCAZZOLA, M; CENTANNI, S; SANTUS, P et al.Respiratory medicine. 2004, Vol 98, Num 12, pp 1214-1221, issn 0954-6111, 8 p.Article

A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challengeSTORMS, William; CHERVINSKY, Paul; GHANNAM, Asma F et al.Respiratory medicine. 2004, Vol 98, Num 11, pp 1051-1062, issn 0954-6111, 12 p.Article

Magicscope containsCOLES, T.Manufacturing chemist (London. 1981). 1998, Vol 69, Num 7, pp 32-33, issn 0262-4230Article

Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.KPRICE, D. B; BEN-JOSEPH, R. H; ZHANG, Q et al.Respiratory medicine. 2001, Vol 95, Num 1, pp 83-89, issn 0954-6111Article

Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPDVESTBO, Jerøen; SORIANO, Joan B; ANDERSON, Julie A et al.Respiratory medicine. 2004, Vol 98, Num 11, pp 1045-1050, issn 0954-6111, 6 p.Conference Paper

Addition of salmeterol to existing treatment in patients with COPD : a 12 month studySTOCKLEY, R. A; CHOPRA, N; RICE, L et al.Thorax. 2006, Vol 61, Num 2, pp 122-128, issn 0040-6376, 7 p.Article

The effects of salmeterol on power output in nonasthmatic athletesMCDOWELL, S. L; FLECK, S. J; STORMS, W. W et al.Journal of allergy and clinical immunology. 1997, Vol 99, Num 4, pp 443-449, issn 0091-6749Article

On the mechanism of the persistent action of salmeterol: what is the current position?COLEMAN, R. A.British journal of pharmacology. 2009, Vol 158, Num 1, pp 180-182, issn 0007-1188, 3 p.Article

Effect of indacaterol, a novel long-acting β₂-agonist, on isolated human bronchiNALINE, E; TRIFILIEFF, A; FAIRHURST, R. A et al.The European respiratory journal. 2007, Vol 29, Num 3, pp 575-581, issn 0903-1936, 7 p.Article

Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionateLUNDBÄCK, Bo; RÖNMARK, Eva; LINDBERG, Anne et al.Respiratory medicine. 2006, Vol 100, Num 1, pp 2-10, issn 0954-6111, 9 p.Article

Tolerance to bronchodilating effects of salmeterol in COPDDONOHUE, J. F; MENJOGE, S; KESTEN, S et al.Respiratory medicine. 2003, Vol 97, Num 9, pp 1014-1020, issn 0954-6111, 7 p.Article

Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled studyJEFFERY, P. K; VENGE, P; GIZYCKI, M. J et al.The European respiratory journal. 2002, Vol 20, Num 6, pp 1378-1385, issn 0903-1936, 8 p.Article

Aerosolisation behaviour of micronised and supercritically-processed powdersSHEKUNOV, Boris Y; FEELEY, Jane C; CHOW, Albert H. L et al.Journal of aerosol science. 2003, Vol 34, Num 5, pp 553-568, issn 0021-8502, 16 p.Article

Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPDCAZZOLA, M; SANTUS, P; DI MARCO, F et al.Respiratory medicine. 2003, Vol 97, Num 5, pp 453-457, issn 0954-6111, 5 p.Article

Validation of a reverse-phase high performance liquid chromatographic method for concurrent assay of a weak base (salmeterol xinafoate) and a pharmacologically active steroid (fluticasone propionate)MURNANE, D; MARTIN, G. P; MARRIOTT, C et al.Journal of pharmaceutical and biomedical analysis. 2006, Vol 40, Num 5, pp 1149-1154, issn 0731-7085, 6 p.Article

Future perspectives in COPDCELLI, Bartolome; GOLDSTEIN, Roger; JARDIM, José et al.Respiratory medicine. 2005, Vol 99, pp S41-S48, issn 0954-6111, SUPBConference Paper

Additive blockade of β₂-integrin adhesion of eosinophils by salmeterol and fluticasone propionateMYO, S; ZHU, X; MYOU, S et al.The European respiratory journal. 2004, Vol 23, Num 4, pp 511-517, issn 0903-1936, 7 p.Article

Desensitisation of mast cell β₂-adrenoceptor-mediated responses by salmeterol and formoterolSCOLA, Anne-Marie; CHONG, Lee K; SUVARNA, S. Kim et al.British journal of pharmacology. 2004, Vol 141, Num 1, pp 163-171, issn 0007-1188, 9 p.Article

Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixturesISLAM, Nazrul; STEWART, Peter; LARSON, Ian et al.Journal of pharmaceutical sciences. 2004, Vol 93, Num 4, pp 1030-1038, issn 0022-3549, 9 p.Article

Influence of Operating Temperature and Pressure on the Polymorphic Transition of Salmeterol Xinafoate in Supercritical FluidsTONG, Henry H. Y; SHEKUNOV, Boris Y; YORK, Peter et al.Journal of pharmaceutical sciences. 2008, Vol 97, Num 2, pp 1025-1029, issn 0022-3549, 5 p.Article

Inhaled beta agonistsOP'T HOLT, Timothy B.Respiratory care. 2007, Vol 52, Num 7, pp 820-832, issn 0020-1324, 13 p.Conference Paper

Salmeterol HFA is as effective as salmeterol CFC in children and adults with persistent asthmaCHOPRA, Narinder; WILLIAMS, Michael; RIMMER, Martin et al.Respiratory medicine. 2005, Vol 99, pp S1-S10, issn 0954-6111, SUPAArticle

Development and performance of a new hydrofluoroalkane (HFA 134a)-based metered dose inhaler (MDI) of salmeterolPEYRON, I. D; BRITTO, I. L; BENISSAN, L. B et al.Respiratory medicine. 2005, Vol 99, pp S20-S30, issn 0954-6111, SUPAArticle

Salmeterol does not alter increased bronchial responsiveness caused by organic dust exposureEK, Alexandra; PALMBERG, Lena; SUNDBLAD, Britt-Marie et al.Chest. 2005, Vol 128, Num 4, pp 3038-3047, issn 0012-3692, 10 p.Article